Action CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Creative Medical Technology Holdings, Inc. Other OTC

Actions

CELZ

US22529Y2000

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Creative Medical Technology Holdings Provides Corporate Update
BU
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
BU
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
BU
Creative Medical Technology Holdings Provides Corporate Update
PR
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain
AQ
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
PR
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine using AlloStem for the Treatment of Chronic Lower Back Pain
AQ
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
PR
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
PR
Creative Medical Technology Announces $2 Million Share Repurchase Program
PR
Creative Medical Technology Holdings Provides Corporate Update
PR
Creative Medical Technology Holdings Announces Reverse Stock Split
PR
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform
PR
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz Platform Development
AQ
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
PR
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine Procedure Using AlloStem Allogenic Cell Line
AQ
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line
PR
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study
PR
Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update
AQ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CELZ
  4. Action CELZ
  5. Actualités Creative Medical Technology Holdings, Inc.
  6. Communiqués
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT